Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Core Insights - Humacyte, Inc. announced the publication of long-term data on Symvess, a bioengineered vessel, demonstrating high limb salvage rates and low infection rates in extremity arterial trauma patients over a follow-up period of up to 36 months [1][2][3] Group 1: Study Results - The study published in the Journal of Vascular Surgery Cases, Innovations and Techniques found that Symvess maintained structural integrity, exhibited a 92.9% infection-free rate from months 3 to 36, and had limb salvage rates of 87.3% at 12 months and 82.5% at 24 months [1][2] - No deaths, amputations, or mechanical failures were attributed to Symvess, and there was no evidence of spontaneous ruptures or structural failures during the follow-up period [2][3] Group 2: Clinical Significance - The results represent the first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit, providing a reliable alternative when autologous vein grafts are not feasible [3][4] - Symvess is designed to be immediately available off-the-shelf, which is critical in emergency situations where time is of the essence [4] Group 3: Company Overview - Humacyte is developing a biotechnology platform for universally implantable bioengineered human tissues and has received FDA approval for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication [13] - The company is also advancing other vascular applications and has received multiple designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) designation for its ATEVs [13]